| *Sponsored
(NYSE American: MAIA) Drops Breaking News Thursday (Chart Support May Be Strengthening) June 5th Greetings, Friend!
MAIA Biotechnology, Inc. (NYSE American: MAIA) has jumped to the top spot on my watchlist for Thursday. Here's why.
Breaking news is taking over the headlines! See what's cooking in MAIA's world today:
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data
CHICAGO, June 05, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron’s immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy.
As of May 15, 2025, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine (the intent-to-treat population) in parts A and B of the trial. The updated analysis continues to demonstrate a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months. The treatment has been generally well-tolerated to date in this heavily pre-treated population.(1) Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.(2-3)
"It is gratifying to see that our treatment further extends lives for these hard-to-treat patient populations, especially in third-line NSCLC treatment where patients are most resistant to therapy," said MAIA Chairman and CEO Vlad Vitoc, M.D. "This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape."
MAIA’s multiple potential regulatory pathways for ateganosine could provide accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year.
Read the full article here.
On top of this massive announcement, MAIA's chart is finding potential support strengthening at 4 key technical levels.
Review my initial (NYSE American: MAIA) report below and think about putting this breakout idea at the top of your watchlist Thursday. -----
There is a remarkable biotech company capturing attention within the medical community for its groundbreaking approach to cancer therapy.
By focusing on the underlying mechanisms that drive tumor growth, this company is addressing critical challenges that have long limited the effectiveness of existing treatments.
Recent clinical data demonstrate significant promise, and the team behind these advancements brings deep expertise and an unwavering commitment to patient outcomes.
As the conversation around next-generation oncology solutions intensifies, this company stands out as a leader to watch.
And here's the kicker. This isn't just any random profile. It's a past champ.
Brought to your a couple months back, it has since catapulted from an alert day's open of $1.95 to a high of $2.74 in May.
That's a move of approximately 40% short term!
After a recent pullback, time could now be ticking once again to consider this breakout idea for your watchlist: MAIA Biotechnology, Inc. (NYSE American: MAIA).
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.
Their lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. | 
